Organogenesis Holdings's ROE % for the quarter that ended in Mar. 2026 was -52.52%. Organogenesis Holdings's PB Ratio for the quarter that ended in Mar. 2026 was 1.24.
Organogenesis Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -42.35%.
Organogenesis Holdings ROE % Adjusted to Book Value Related Terms
Organogenesis Holdings ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings ROE % Adjusted to Book Value Chart
FRA:2PQ vs TKNO, AKBA, SIGA: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -42.35% mean?
Organogenesis Holdings (FRA:2PQ) has a ROE % Adjusted to Book Value of -42.35% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' ROE % Adjusted to Book Value too high?
Organogenesis Holdings' current ROE % Adjusted to Book Value is -42.35%. Overall, Organogenesis Holdings has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' ROE % Adjusted to Book Value compare to TKNO and AKBA?
Organogenesis Holdings' ROE % Adjusted to Book Value of -42.35% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current ROE % Adjusted to Book Value is -42.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.68, compared to a current price of €2.06 — trading 23.1% below its estimated fair value. The current ROE % Adjusted to Book Value is -42.35%. Organogenesis Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current ROE % Adjusted to Book Value is -42.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.06 is trading 23.1% below its estimated GF Value™ of €2.68.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for FRA:2PQ:
ROE % Adjusted to Book Value: -42.35%
GF Value™: €2.68 vs. price of €2.06 (23.1% below fair value)
No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
65GF Score
Get the complete analysis for FRA:2PQ
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2PQ has been successfully added to your 
